Midostaurin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Midostaurin: From FLT3-Mutated AML/Systemic Mastocytosis to Familial Thrombocytosis
Note: The evidence pack contains no Australian regulatory record for midostaurin’s original indication (ARTG entries = 0, market status = Not marketed). The original indication above is well-established public pharmacological information (Rydapt®, approved overseas for FLT3-mutated AML and aggressive systemic mastocytosis) and is not sourced from this Evidence Pack — flagged here for transparency rather than fabricated as pack data.
One-Sentence Summary
Midostaurin is a multikinase inhibitor (FLT3/KIT/PDGFR/VEGFR2/PKC) originally developed for FLT3-mutated acute myeloid leukaemia and systemic mastocytosis. The TxGNN model predicts it may be effective for Familial Thrombocytosis, but this prediction currently has no supporting clinical trials and no supporting literature, and the pack’s own mechanistic review states the pathway driving familial thrombocytosis (MPL/THPO germline mutations) does not overlap with midostaurin’s known targets.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in Evidence Pack (drug not ARTG-registered in Australia) |
| Predicted New Indication | Familial Thrombocytosis |
| TxGNN Prediction Score | 98.92% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed structured MOA data is not available from DrugBank in this Evidence Pack (flagged as a High-severity data gap). However, literature captured elsewhere in this pack (PMID 16969355) independently describes midostaurin (PKC412A) as a multikinase inhibitor that potently inhibits protein kinase C alpha (PKCα), VEGFR2, KIT, PDGFR and FLT3 tyrosine kinases.
Familial thrombocytosis is a hereditary platelet disorder driven almost exclusively by germline mutations in MPL (thrombopoietin receptor) or THPO (thrombopoietin) — pathways that constitutively activate JAK-STAT signalling. This is a distinct mechanism from the FLT3/KIT/PKC axis that midostaurin targets.
The evidence pack’s own repurposing rationale for this candidate is explicit on this point: the disease’s causative pathway does not involve FLT3/KIT/PKC, so there is no direct mechanistic link to midostaurin’s known pharmacology. The high TxGNN score most likely reflects node proximity within the knowledge graph (e.g. shared association with platelet/myeloid biology broadly) rather than a genuine, validated biological connection. This is consistent with the L5 evidence tier (model prediction only, no supporting studies) and the “Hold” recommendation.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Australia Market Information
No ARTG entries — midostaurin is not currently marketed in Australia according to this Evidence Pack.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but this candidate has zero clinical trial or literature support, and the pack’s own mechanistic analysis indicates the target disease pathway (MPL/THPO-driven) does not intersect with midostaurin’s known kinase targets (FLT3/KIT/PKC). Evidence is insufficient to justify further evaluation at this time.
To proceed, the following is needed:
- Structured DrugBank MOA data (currently a Blocking/High data gap in this pack)
- TFDA/TGA Product Information warnings and contraindications (Blocking gap — required before any S1 safety screening)
- In vitro or preclinical validation of any interaction between midostaurin’s targets and the MPL/THPO/JAK-STAT pathway, before this candidate can move beyond model prediction
For context: among the other candidates in this pack, thrombocythemia (rank 5, evidence level L4, “Research Question”) has a somewhat stronger — though still preclinical/indirect — mechanistic basis via FLT3-driven myeloproliferative neoplasm models, and metastatic melanoma (rank 3, L3) already has a negative Phase IIA clinical result. Neither is in scope of this report, which follows the pack’s top-ranked candidate (familial thrombocytosis) per protocol.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.